Biopharma · FDA Approvals · Stock

ANVS Annovis Bio

Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase …

Assets on file: buntanetap

Start live analysis of ANVS Run 8-agent AI analysis All sector events →

Catalyst calendar

Dated catalysts for ANVS, including recently decided ones.

December 2027

Dec 2027

~ Dec 2027

ANVSAnnovis Bio

buntanetap: Phase 3 trial NCT06709014 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

September 2029

Sep 2029

~ Sep 2029

ANVSAnnovis Bio

buntanetap: Phase 2/Phase 3 trial NCT07284784 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

February 2030

Feb 2030

Feb 21, 2030

in 1209 days

ANVSAnnovis Bio

buntanetap: Phase 2/Phase 3 trial NCT07757204 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Recent first-hand events

Every first-hand event for ANVS, newest first.

Instant stream — events appear as soon as they are filed.

Decision-gradeMaterialNotableMinor

Oct 30, 2026

03:22 PM

ANVSAnnovis Bio

buntanetap · NCT07284784 registry update

countries: {'total_sites': 27, 'us_sites': 27} → {'total_sites': 29, 'us_sites': 29}

Trial registry changeClinicalTrials.gov

Jul 10, 2026

01:06 AM

ANVSAnnovis Bio

Annovis completes full enrollment of Phase 3 buntanetap AD trial

The pivotal Phase 3 trial of buntanetap in early Alzheimer’s disease has reached full enrollment of 850 patients, exceeding the original target. The dual-readout design remains unchanged, with symptomatic data expected in Q1 2027 and disease-modifying data in Q1 2028, each intended to support a separate NDA submission.

Trial registry changeSEC 8-K

May 15, 2026

08:00 PM

ANVSAnnovis Bio

Annovis closes AD Phase 3 screening; 85% enrolled

Annovis closed new screening for its pivotal Phase 3 AD trial (NCT06709014) on 15 May 2026 after reaching a sufficient pool to complete randomization. The study remains on track for full enrollment in summer 2026, with symptomatic data expected ~6 months after last patient dosed and disease-modifying data at 18 months.

Trial registry changeSEC 8-K